In 2022, the most-read articles published in Evidence-Based Oncology™ included the latest updates in cancer treatments, the promises and challenges of technology, and a look at the shifting landscape of care delivery.
The latest updates in cancer treatments, the promises and challenges of technology, and a look at the shifting landscape of care delivery were among the most-read articles published in Evidence-Based Oncology™ (EBO) in 2022.
Here are the top 5 most-read EBO articles of the year.
5. COTA’s Miruna Sasu on Real-world Evidence: “The Ecosystem Has Changed”
In March 2022, Miruna Sasu, PhD, MBA, became the president and CEO of COTA Healthcare, which provides real-world data abstraction, curation, and analytics capabilities in oncology to health care provider organizations and life sciences companies.
In this Q&A, Sasu discusses her new role, the changing field of real-world data and real-world evidence, how the FDA can facilitate greater use of real-world data, and more.
4. The Promise of Telehealth—a Cautionary Tale
This article was the second in a series of 2 from Neil Minkoff, MD, founder of FountainHead HealthCare and chief medical officer of COEUS Consulting Group. Minkoff, a longtime friend of and frequent collaborator with The American Journal of Managed Care® (AJMC®), died suddenly on May 4, 2022. His colleagues worked to finalize this 2-part series on the future of telehealth. The first part appeared online in September, and this second part ran in the October issue of EBO.
In this article, Minkoff and his colleagues discuss how many oncology practices embraced telehealth during the COVID-19 pandemic, but at-home medication administration may pose safety and practice management concerns for oncologists.
3. NCCN Update Moves Zanubrutinib Ahead of Ibrutinib in CLL/SLL Based on Toxicity Profile
Data on zanubrutinib in chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) have highlighted its superior overall response rate compared with ibrutinib. While the FDA is still weighing approval of the drug—a target action date is set for January 20, 2023—the National Comprehensive Cancer Network (NCCN) guidelines committee has already made its own decision.
NCCN updated its guidelines to place the second-generation Bruton tyrosine kinase inhibitor (BTK) ahead of ibrutinib. The decision was partly centered on ibrutinib’s toxicity profile and the fact that the first-generation BTK inhibitor has known “off-target” cardiac effects.
2. Inovio's DNA Vaccine Combo Plus Cemiplimab Shows Promise in Glioblastoma
Study results presented at the 2022 American Society of Clinical Oncology annual meeting showed that a pair of DNA medicines combined with cemiplimab (Libtayo), a checkpoint inhibitor, produced promising overall survival results in glioblastoma. Other cancers have seen progress with checkpoint inhibitors, but glioblastoma has been one area where immunotherapies have not worked as well.
The study showed the regimen was well tolerated and adverse events were consistent with those seen in other studies of checkpoint inhibitors. However, there need to be additional studies to confirm the findings.
1. Shifting Landscape of Care Delivery Is Impacting Value-Based Cancer Care
At the June meeting of AJMC®’s Institute for Value-Based Medicine®, held with Texas Oncology in Austin, Texas, speakers discussed how value-based cancer care needs to protect community oncology, which has allowed patients to receive care close to where they live and minimize travel to large medical centers.
Other shifts in the landscape impacting value that were discussed at the event were the vertical integration of payers, pharmacy benefit managers, and specialty pharmacies, and the increasing use of oral therapies.